PCSK9 and coronary artery disorder: Use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, in addition to lowering LDL cholesterol (LDL-C) decreases Lp(a), and this action has been reported to contribute to the reduction in CHD endpoints seen in clinical trials 6, 7.